Baron Financial Group’s Kyntra Bio KYNB Stock Holding History

Baron Financial Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-400	Closed	-$187K	–	55
2023 Q1	$187K	Buy	+400	New	+$212K	0.12%	55

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baron Financial Group's KYNB Position: Q2 2023 in Review

Baron Financial Group sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 400 shares — an estimated $187K sold.

Baron Financial Group first reported a position in KYNB in Q1 2023 and held it in 1 quarter. The position peaked at $187K in Q1 2023. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

Baron Financial Group reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
Baron Financial Group sold 400 Kyntra Bio shares in Q2 2023, an estimated $187K.
Baron Financial Group first reported a position in Kyntra Bio in Q1 2023 and held it in 1 quarter.
Baron Financial Group's Kyntra Bio position peaked at $187K in Q1 2023.
152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Baron Financial Group's 13F filing for Q2 2023, filed 3 Aug 2023.